Skip to content
AnalystLens

Idex 8-K Report, Financial Results (Oct 28, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed October 28, 2026
Period End
October 28, 2026
Security
IEX
In the record · 2016–202610-K1110-Q338-K119

IEX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jun ’16Jun ’16
  2. Material agreement8-K · Jun ’19Jun ’19
  3. Leadership change8-K · Feb ’22Feb ’22
  4. Leadership change8-K · Dec ’25Dec ’25

Summary

Summary of the 8-K filed October 28, 2026. Cited figures are marked; the original filing is the authoritative source.

IDEX Corporation reported record third-quarter 2026 results, with net sales of $951.7 milliona, up 8% on both a reported and organic basis versus the prior year period.

Reported diluted EPS attributable to IDEX was $1.95b, up from $1.70, and record adjusted diluted EPS was $2.33, up from $2.03, with both reported and adjusted EPS increasing 15%. Orders were $991.2 million, up 13% on both a reported and organic basis. Gross margin rose to 45.1% from 44.5%, and Adjusted EBITDA margin rose to 27.8% from 27.3%.

The Health & Science Technologies segment drove much of the growth, with net sales up 14% and organic sales up 13%, supported by AI-driven demand for data center power and semiconductor markets, as well as space and defense. Cash flow was strong, with operating cash flow of $239.5 millionc and free cash flow of $214.3 million, compared with $188.7 million a year earlier. The company returned $129 million to shareholders through dividends and share repurchases during the quarter, and it amended and restated its $800 million revolving credit facility to extend maturity to September 2031.

Management raised full-year 2026 guidance, now projecting organic sales growth of 6.5% to 6.8%, up from 5% to 6%, and adjusted diluted EPS of $8.91 to $8.96d, up from $8.70 to $8.85. The filing furnishes the earnings press release as Exhibit 99.1 under Item 2.02, and that information is not deemed filed for Section 18 purposes.

Key Highlights

  1. Record third-quarter net sales of $951.7 million, up 8% on both a reported and organic basis
  2. Reported diluted EPS of $1.95 and record adjusted diluted EPS of $2.33, both up 15%
  3. Orders of $991.2 million, up 13% on both a reported and organic basis
  4. Health & Science Technologies segment net sales rose 14%, with organic growth of 13% driven by AI-related data center power and semiconductor demand
  5. Full-year 2026 guidance raised: organic sales growth of 6.5% to 6.8% and adjusted diluted EPS of $8.91 to $8.96
  6. Operating cash flow of $239.5 million and free cash flow of $214.3 million in the quarter, both higher than the prior year
  7. Returned $129 million to shareholders via dividends and share repurchases; revolving credit facility amended and extended to September 2031

Frequently Asked Questions

  1. How did IDEX perform in the third quarter of 2026?

    Net sales were a record $951.7 million, up 8% reported and organically. Gross margin increased to 45.1% from 44.5%, and Adjusted EBITDA margin increased to 27.8% from 27.3%. Net income attributable to IDEX was $144.1 million, compared with $127.8 million in the prior year period.

  2. What drove the growth in the quarter?

    The filing attributes the organic sales increase to higher volumes, primarily in the Health & Science Technologies segment, and positive price across the segments. Management cites AI-driven demand for data center power and semiconductor markets, along with strength in space and defense.

  3. Did IDEX change its full-year outlook?

    Yes. Full-year organic sales growth is now projected at 6.5% to 6.8%, up from 5% to 6%. Full-year adjusted diluted EPS is now expected to be $8.91 to $8.96, up from $8.70 to $8.85. The company notes that it does not reconcile these forward-looking non-GAAP measures to U.S. GAAP because certain items cannot be reasonably estimated without unreasonable effort.

  4. How strong was cash generation and capital return?

    Operating cash flow was $239.5 million, versus $203.5 million a year earlier, and free cash flow was $214.3 million, versus $188.7 million. The company returned $129 million to shareholders through dividends and share repurchases during the quarter.

  5. What was the order performance?

    Orders were $991.2 million, up 13% on both a reported and organic basis, compared with $880.3 million in the prior year period. Management described booking nearly $1 billion in orders in the quarter.